Document Detail

Immune status of human immunodeficiency virus seropositive and seronegative hemophiliacs infused for 3.5 years with recombinant factor VIII. The Kogenate Study Group.
MedLine Citation:
PMID:  7908234     Owner:  NLM     Status:  MEDLINE    
Recent studies suggest that treatment of hemophiliacs with highly purified factor VIII concentrates may preserve immune function. To test this hypothesis, we prospectively studied 51 hemophilic patients (21 human immunodeficiency virus [HIV] seropositive and 30 seronegative) who were on home therapy exclusively with recombinant factor VIII (Kogenate, Miles Laboratory, Berkeley, CA) for 3.5 years. Patients, all of whom had been previously treated with plasma-derived factor VIII concentrates, were monitored every 6 months with T-lymphocyte subsets and beta 2-microglobulin levels. Mean rate of change in absolute CD4 cell counts, calculated from regression slopes for individual patients, showed a small but statistically significant decrease over the 3.5-year study period for HIV seropositive hemophiliacs. No decrease in CD4 cell counts was seen in HIV seronegative hemophiliacs when the data for children under age 6 years were excluded from the analysis. beta 2-microglobulin levels and CD8 cell counts remained unchanged. These data show stability of immunologic parameters in HIV seronegative hemophiliacs, and a small decrease in CD4 cell counts in HIV seropositive hemophiliacs treated with recombinant factor VIII.
P M Mannucci; D B Brettler; L M Aledort; J M Lusher; C F Abildgaard; R S Schwartz; D Hurst
Related Documents :
10482364 - Reduction of viral load and immune complex load on cd4+ lymphocytes as a consequence of...
12004324 - Idiopathic cd4+t-cell lymphocytopenia associated with vitiligo.
6697004 - Steroid responsive cyclical neutropenia.
16859054 - Frequency of positive purified protein derivative test in those infected with human imm...
7576034 - Serum reactivity against an immunoregulatory sequence of hiv p24 in hiv-1-infected subj...
2237274 - Alcoholic hepatitis: pathogenesis and approaches to treatment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Blood     Volume:  83     ISSN:  0006-4971     ISO Abbreviation:  Blood     Publication Date:  1994 Apr 
Date Detail:
Created Date:  1994-05-05     Completed Date:  1994-05-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1958-62     Citation Subset:  AIM; IM; X    
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antigens, CD8 / analysis
CD4-Positive T-Lymphocytes
Factor VIII / therapeutic use*
HIV Seronegativity / immunology*
HIV Seropositivity / immunology*
Hemophilia A / immunology*,  therapy
Leukocyte Count
Recombinant Proteins / therapeutic use
beta 2-Microglobulin / analysis
Reg. No./Substance:
0/Antigens, CD8; 0/Recombinant Proteins; 0/beta 2-Microglobulin; 9001-27-8/Factor VIII

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The cell and molecular basis of leukocyte common antigen (CD45)-triggered, lymphocyte function-assoc...
Next Document:  Acquisition of CD13 and CD33 expression at relapse on acute myeloid leukemia cells with an unusual p...